Alban Ziegler,Carrie Koval-Burt,Denise M Kay,Sharon F Suchy,Amber Begtrup,Katherine G Langley,Rebecca Hernan,Laura M Amendola,Brenna M Boyd,Jennifer Bradley,Tracy Brandt,Lilian L Cohen,Alison J Coffey,Joseph M Devaney,Beata Dygulska,Bethany Friedman,Ramsay L Fuleihan,Awura Gyimah,Sihoun Hahn,Sean Hofherr,Kathleen S Hruska,Zhanzhi Hu,Médéric Jeanne,Guanjun Jin,D Aaron Johnson,Haluk Kavus,Rudolph L Leibel,Steven J Lobritto,Stephen McGee,Joshua D Milner,Kirsty McWalter,Kristin G Monaghan,Jordan S Orange,Nicole Pimentel Soler,Yeyson Quevedo,Samantha Ratner,Kyle Retterer,Ankur Shah,Natasha Shapiro,Robert J Sicko,Eric S Silver,Samuel Strom,Rebecca I Torene,Olatundun Williams,Vincent D Ustach,Julia Wynn,Ryan J Taft,Paul Kruszka,Michele Caggana,Wendy K Chung

Abstract:Importance: The feasibility of implementing genome sequencing as an adjunct to traditional newborn screening (NBS) in newborns of different racial and ethnic groups is not well understood. Objective: To report interim results of acceptability, feasibility, and outcomes of an ongoing genomic NBS study in a diverse population in New York City within the context of the New York State Department of Health Newborn Screening Program. Design, setting, and participants: The Genomic Uniform-screening Against Rare Disease in All Newborns (GUARDIAN) study was a multisite, single-group, prospective, observational investigation of supplemental newborn genome screening with a planned enrollment of 100 000 participants. Parent-reported race and ethnicity were recorded at the time of recruitment. Results of the first 4000 newborns enrolled in 6 New York City hospitals between September 2022 and July 2023 are reported here as part of a prespecified interim analysis. Exposure: Sequencing of 156 early-onset genetic conditions with established interventions selected by the investigators were screened in all participants and 99 neurodevelopmental disorders associated with seizures were optional. Main outcomes and measures: The primary outcome was screen-positive rate. Additional outcomes included enrollment rate and successful completion of sequencing. Results: Over 11 months, 5555 families were approached and 4000 (72.0%) consented to participate. Enrolled participants reflected a diverse group by parent-reported race (American Indian or Alaska Native, 0.5%; Asian, 16.5%; Black, 25.1%; Native Hawaiian or Other Pacific Islander, 0.1%; White, 44.7%; 2 or more races, 13.0%) and ethnicity (Hispanic, 44.0%; not Hispanic, 56.0%). The majority of families consented to screening of both groups of conditions (both groups, 90.6%; disorders with established interventions only, 9.4%). Testing was successfully completed for 99.6% of cases. The screen-positive rate was 3.7%, including treatable conditions that are not currently included in NBS. Conclusions and relevance: These interim findings demonstrate the feasibility of targeted interpretation of a predefined set of genes from genome sequencing in a population of different racial and ethnic groups. DNA sequencing offers an additional method to improve screening for conditions already included in NBS and to add those that cannot be readily screened because there is no biomarker currently detectable in dried blood spots. Additional studies are required to understand if these findings are generalizable to populations of different racial and ethnic groups and whether introduction of sequencing leads to changes in management and improved health outcomes. Trial registration: ClinicalTrials.gov Identifier: NCT05990179.

A systematic framework for selecting gene-condition pairs for inclusion in newborn sequencing panels: Early Check implementation

Application of a Next-Generation Sequencing (NGS) Panel in Newborn Screening Efficiently Identifies Inborn Disorders of Neonates

Data-driven prioritization of genetic disorders for global genomic newborn screening programs

Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions

Early Intervention services in the era of genomic medicine: setting a research agenda

Genomic Sequencing As a First-Tier Screening Test and Outcomes of Newborn Screening.

Gene selection for genomic newborn screening: moving towards consensus?

SeqFirst: Building equity access to a precise genetic diagnosis in critically ill newborns

Counting Conditions on Newborn Bloodspot Screening Panels in Australia and New Zealand

Comparative analysis of gene and disease selection in genomic newborn screening studies

Lessons Learned from Expanded Reproductive Carrier Screening in Self‐reported Ashkenazi, Sephardi, and Mizrahi Jewish Patients

Prequalification of genome-based newborn screening for severe childhood genetic diseases through federated training based on purifying hyperselection

Prospective Prenatal Cell-Free DNA Screening for Genetic Conditions of Heterogenous Etiologies

Early readout shows promise of genomic newborn screening

A genome sequencing system for universal newborn screening, diagnosis, and precision medicine for severe genetic diseases

Newborn screening with targeted sequencing: a multicenter investigation and a pilot clinical study in China

Genome-based newborn screening for severe childhood genetic diseases has high positive predictive value and sensitivity in a NICU pilot trial

Universal newborn screening using genome sequencing: early experience from the GUARDIAN study

Wilson and Jungner Revisited: Are Screening Criteria Fit for the 21st Century?

A Modular Genetic Approach to Newborn Screening from Spinal Muscular Atrophy to Sickle Cell Disease—Results from Six Years of Genetic Newborn Screening

Feasibility and Acceptability of a Newborn Screening Program Using Targeted Next-Generation Sequencing in One Maternity Hospital in Southern Belgium